46.30
price up icon1.40%   0.64
after-market 시간 외 거래: 46.30
loading
전일 마감가:
$45.66
열려 있는:
$45.61
하루 거래량:
1.51M
Relative Volume:
0.50
시가총액:
$8.79B
수익:
$217.77M
순이익/손실:
$-438.86M
주가수익비율:
-19.21
EPS:
-2.41
순현금흐름:
$-456.33M
1주 성능:
-0.45%
1개월 성능:
+4.33%
6개월 성능:
+23.17%
1년 성능:
+73.41%
1일 변동 폭
Value
$45.27
$46.41
1주일 범위
Value
$45.27
$47.40
52주 변동 폭
Value
$21.72
$48.68

Bridgebio Pharma Inc Stock (BBIO) Company Profile

Name
명칭
Bridgebio Pharma Inc
Name
전화
(650) 391-9740
Name
주소
3160 PORTER DR., PALO ALTO, CA
Name
직원
730
Name
트위터
Name
다음 수익 날짜
2024-10-31
Name
최신 SEC 제출 서류
Name
BBIO's Discussions on Twitter

BBIO을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
BBIO
Bridgebio Pharma Inc
46.30 8.67B 217.77M -438.86M -456.33M -2.41
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
469.65 121.28B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
563.10 60.96B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
328.81 42.77B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
591.99 36.21B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
291.47 32.08B 3.81B -644.79M -669.77M -6.24

Bridgebio Pharma Inc Stock (BBIO) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2025-07-21 개시 Truist Buy
2025-07-14 개시 Jefferies Buy
2025-07-09 업그레이드 Oppenheimer Perform → Outperform
2025-06-17 개시 Wolfe Research Outperform
2025-03-31 개시 Redburn Atlantic Buy
2024-10-16 개시 Scotiabank Sector Outperform
2024-10-03 개시 Oppenheimer Perform
2024-09-04 개시 Piper Sandler Overweight
2024-03-21 재개 Raymond James Outperform
2024-01-31 개시 BMO Capital Markets Market Perform
2023-12-08 개시 Wells Fargo Overweight
2023-11-07 개시 Citigroup Buy
2023-10-24 개시 Cantor Fitzgerald Overweight
2023-07-18 다운그레이드 Jefferies Buy → Hold
2023-04-19 개시 Evercore ISI Outperform
2023-02-06 개시 Cowen Outperform
2021-12-27 재확인 Mizuho Buy
2021-12-27 재확인 SVB Leerink Outperform
2021-09-10 업그레이드 BofA Securities Neutral → Buy
2021-05-21 개시 UBS Buy
2021-03-22 재확인 Goldman Buy
2021-02-22 재개 JP Morgan Overweight
2021-02-09 재개 Goldman Buy
2021-01-11 재확인 H.C. Wainwright Buy
2020-12-10 재확인 H.C. Wainwright Buy
2020-06-25 개시 BofA/Merrill Neutral
2020-05-19 개시 BTIG Research Buy
2020-04-13 개시 H.C. Wainwright Buy
2020-02-19 개시 Mizuho Buy
2019-07-26 개시 Raymond James Outperform
2019-07-22 개시 BMO Capital Markets Outperform
2019-07-22 개시 Goldman Buy
2019-07-22 개시 JP Morgan Overweight
2019-07-22 개시 Jefferies Buy
2019-07-22 개시 Piper Jaffray Overweight
2019-07-22 개시 SVB Leerink Outperform
모두보기

Bridgebio Pharma Inc 주식(BBIO)의 최신 뉴스

pulisher
10:53 AM

What are the latest earnings results for BridgeBio Pharma Inc.Massive portfolio appreciation - jammulinksnews.com

10:53 AM
pulisher
Jul 26, 2025

Leerink Partners Maintains a Buy on BridgeBio Pharma (BBIO) With a $56 PT - MSN

Jul 26, 2025
pulisher
Jul 26, 2025

Why BridgeBio Pharma Inc. stock attracts strong analyst attentionMassive Profit Potential - Metal.it

Jul 26, 2025
pulisher
Jul 26, 2025

Truist Sees Upside in BridgeBio Pharma’s (BBIO) ATTR-CM Strategy - MSN

Jul 26, 2025
pulisher
Jul 26, 2025

Will BridgeBio Pharma Inc. stock benefit from interest rate changesFree Stock Market Forecasting Tools - Metal.it

Jul 26, 2025
pulisher
Jul 25, 2025

Why BridgeBio Pharma Inc. stock is on top investor watchlistsMarket-leading growth rates - jammulinksnews.com

Jul 25, 2025
pulisher
Jul 24, 2025

What drives BridgeBio Pharma Inc. stock priceFree Stock Market Query - PrintWeekIndia

Jul 24, 2025
pulisher
Jul 24, 2025

Bridgebio Pharma shares rise 1.97% premarket after novel human genetics evidence confirms estimates of genetic prevalence and underdiagnosis of ADH1. - AInvest

Jul 24, 2025
pulisher
Jul 23, 2025

10 Best Biotech Stocks to Buy According to Billionaire Steve Cohen - Insider Monkey

Jul 23, 2025
pulisher
Jul 23, 2025

Groundbreaking Genetics Study Uncovers 25,000 Hidden ADH1 Cases in US and EU, Most Patients Undiagnosed - Stock Titan

Jul 23, 2025
pulisher
Jul 23, 2025

BridgeBio Pharma Inc. Stock Analysis and ForecastConsistently profitable trades - jammulinksnews.com

Jul 23, 2025
pulisher
Jul 22, 2025

Is BridgeBio Pharma Inc. a good long term investmentOutstanding risk-reward balance - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

What analysts say about BridgeBio Pharma Inc. stockRobust investment performance - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

BridgeBio to Host Second Quarter 2025 Financial Results Conference Call on Tuesday, August 5, 2025 at 4:30 pm ET - The Manila Times

Jul 22, 2025
pulisher
Jul 22, 2025

BridgeBio Pharma, Inc. Scheduled to Release Q2 Financial Results and Business Updates on August 5, 2025 - Nasdaq

Jul 22, 2025
pulisher
Jul 22, 2025

BridgeBio, Genetic Disease Pioneer, Sets Q2 2025 Earnings Release DateKey Details Inside - Stock Titan

Jul 22, 2025
pulisher
Jul 21, 2025

Truist Securities Initiates Coverage on BridgeBio Pharma with 'Buy' Rating and $66 Price Target - AInvest

Jul 21, 2025
pulisher
Jul 21, 2025

BridgeBio Pharma Stock (BBIO) Opinions on Analyst Buy Ratings and Attruby Launch - Quiver Quantitative

Jul 21, 2025
pulisher
Jul 21, 2025

BridgeBio stock initiated with Buy rating at Truist on strong Attruby launch - Investing.com Canada

Jul 21, 2025
pulisher
Jul 21, 2025

BridgeBio Pharma (BBIO) Receives New 'Buy' Rating from Truist Se - GuruFocus

Jul 21, 2025
pulisher
Jul 18, 2025

BridgeBio Pharma stock maintains Buy rating at H.C. Wainwright after royalty deal - Investing.com Canada

Jul 18, 2025
pulisher
Jul 16, 2025

These 2 Momentum Stocks Got a Bullish Nod — Here’s Why They Could Reach New Highs - The Globe and Mail

Jul 16, 2025
pulisher
Jul 16, 2025

Jefferies Initiates BridgeBio Pharma(BBIO.US) With Buy Rating, Announces Target Price $70 - 富途牛牛

Jul 16, 2025
pulisher
Jul 15, 2025

Scotiabank Sticks to Its Buy Rating for BridgeBio Pharma (BBIO) - The Globe and Mail

Jul 15, 2025
pulisher
Jul 15, 2025

Citi reiterates Buy rating on BridgeBio stock ahead of key trial data - Investing.com Canada

Jul 15, 2025
pulisher
Jul 14, 2025

Trading (BBIO) With Integrated Risk Controls - news.stocktradersdaily.com

Jul 14, 2025
pulisher
Jul 14, 2025

BridgeBio Pharma (BBIO) Receives Buy Rating from Jefferies | BBIO Stock News - GuruFocus

Jul 14, 2025
pulisher
Jul 14, 2025

Citi Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Maintains Target Price $67 - 富途牛牛

Jul 14, 2025
pulisher
Jul 14, 2025

Jefferies Initiates Coverage of BridgeBio Pharma (BBIO) with Buy Recommendation - MSN

Jul 14, 2025
pulisher
Jul 14, 2025

BridgeBio Pharma stock initiated with Buy rating at Jefferies on Attruby potential - Investing.com Canada

Jul 14, 2025
pulisher
Jul 13, 2025

BridgeBio Pharma Raises $300M Through Partial European Royalty Monetization for BEYONTTRA - MSN

Jul 13, 2025
pulisher
Jul 13, 2025

BridgeBio Pharma's BBP-418: A Promising Investment in Groundbreaking LGMD2I/R9 Therapy - AInvest

Jul 13, 2025
pulisher
Jul 12, 2025

BridgeBio (BBIO) Tanks After Selling Beyonttra Royalty Rights - MSN

Jul 12, 2025
pulisher
Jul 12, 2025

Helix shareholders to vote on BridgeBio Oncology merger on August 4 By Investing.com - Investing.com Nigeria

Jul 12, 2025
pulisher
Jul 12, 2025

Helix shareholders to vote on BridgeBio Oncology merger on August 4 - Investing.com Australia

Jul 12, 2025
pulisher
Jul 11, 2025

Cancer-Focused BridgeBio's $949M SPAC Deal Gets SEC Nod - Law360

Jul 11, 2025
pulisher
Jul 11, 2025

BridgeBio Oncology's SPAC Merger Advances: SEC Clears Path for Novel Cancer Drug Development Platform - Stock Titan

Jul 11, 2025
pulisher
Jul 10, 2025

BridgeBio Pharma stock hits 52-week high, reaching $45.53 By Investing.com - Investing.com South Africa

Jul 10, 2025

Bridgebio Pharma Inc (BBIO) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading

Bridgebio Pharma Inc 주식 (BBIO) 내부자 거래

내부자 거래 관계 날짜 거래 비용 #주식 가치 ($) #주식 총계
Kumar Neil
Chief Executive Officer
Jul 01 '25
Sale
42.54
40,000
1,701,400
975,686
VIKING GLOBAL INVESTORS LP
10% Owner
Jun 27 '25
Sale
44.00
3,500,000
154,000,000
18,555,375
$23.40
price down icon 0.97%
$36.67
price up icon 0.22%
$103.95
price up icon 0.42%
$28.67
price up icon 3.99%
$115.31
price up icon 0.65%
biotechnology ONC
$291.47
price down icon 1.68%
자본화:     |  볼륨(24시간):